BioMarin deal pays Amicus (NASDAQ: FOLD) director $14.50 per share
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
AMICUS THERAPEUTICS director Burke W. Whitman reported a full disposition of his equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical Inc.
He disposed of 118,598 shares of Common Stock at $14.50 per share, a figure that includes 98,184 common shares and 20,414 restricted stock units that vested in full when the merger closed. Following this transaction, he no longer holds Amicus common stock.
Multiple fully vested stock option awards, each giving the right to buy Amicus common stock at exercise prices between $5.96 and $12.81 per share, were also cancelled at closing. Each option was converted into a cash payment equal to the difference between $14.50 per share and its exercise price, multiplied by the number of shares subject to that option, leaving no remaining Amicus options outstanding for this director.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
WHITMAN BURKE W
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Options (right to buy) | 25,964 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 18,574 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 36,111 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 45,423 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 30,474 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 42,467 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 74,872 | $0.00 | -- |
| Disposition | Common Stock | 118,598 | $14.50 | $1.72M |
Holdings After Transaction:
Stock Options (right to buy) — 0 shares (Direct, null);
Common Stock — 0 shares (Direct, null)
Footnotes (1)
- The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 98,184 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger). In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. Each Option vested in full in connection with consummation of the Merger.
Key Figures
Common shares disposed: 118,598 shares at $14.50/share
Common shares component: 98,184 shares
Restricted stock units vested: 20,414 units
+4 more
7 metrics
Common shares disposed
118,598 shares at $14.50/share
Common Stock disposition in connection with BioMarin merger
Common shares component
98,184 shares
Portion of 118,598 shares identified as Common Stock
Restricted stock units vested
20,414 units
RSUs vesting in full upon consummation of the merger
Option exercise price
$5.96/share
One cancelled stock option’s exercise price, settled vs $14.50
Option exercise price
$10.27/share
Another cancelled stock option’s exercise price, settled vs $14.50
Option exercise price
$12.81/share
Cancelled stock option exercise price, settled at $14.50 merger price
Post-transaction holdings
0 shares, 0 derivatives
Total Amicus equity held by Burke Whitman after merger settlement
Key Terms
restricted stock units, stock option, Merger, cash payment, +1 more
5 terms
restricted stock units financial
"20,414 restricted stock units (which vested in full in connection with consummation of the Merger)"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"In connection with consummation of the Merger, each reported stock option ("Option") was cancelled"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Merger financial
"consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger")"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
cash payment financial
"was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share"
exercise price financial
"equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
